The AllTrials Campaign: Evolution, Impact, and Barriers

Introduction to the AllTrials Campaign

The AllTrials Campaign was launched in 2013 as a global movement to demand that all clinical trials—past and present—be registered and have their results reported. Initiated by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, the campaign quickly gained international traction and has since reshaped conversations around clinical transparency, ethics, and accountability in medical research.

The campaign’s motto, “All Trials Registered. All Results Reported.”, has become a rallying cry for researchers, regulatory bodies, journals, and patient advocacy groups. The underlying concern is simple yet urgent: missing clinical trial results distort the evidence base used by clinicians, regulators, and policymakers to make decisions about patient care.

Founding Organizations and Strategic Goals

The AllTrials campaign is driven by several well-respected organizations. Cochrane’s data-driven research approach, BMJ’s editorial stance, and the statistical scrutiny promoted by Goldacre’s initiatives have created a compelling synergy. The core objectives of the campaign include:

• Mandating public registration of all clinical trials at inception
• Ensuring timely disclosure of trial results, regardless of outcome
• Retrospective disclosure of older, unpublished trials
• Policy change at institutional, national, and international levels

Over time, the campaign has helped push forward policy reform and sponsor accountability. For example, many institutions now require ClinicalTrials.gov or EudraCT registration as a condition for IRB approval or journal publication.

Successes Achieved Through Advocacy and Policy Reform

Since its inception, AllTrials has garnered support from over 750 organizations worldwide, including universities, research sponsors, regulators, and patient groups. The campaign has led to tangible policy changes:

• The European Medicines Agency (EMA) launched a database to make clinical data publicly accessible.
• The U.S. Final Rule (FDAAA 801) clarified disclosure expectations and timelines.
• WHO’s Joint Statement echoed many of AllTrials’ demands for transparency.
• The UK Health Research Authority issued mandates to enforce trial result reporting.

These achievements mark a significant shift toward transparency becoming an expected, if not legally enforceable, norm. Tools like the FDAAA Trials Tracker help monitor sponsor compliance in real time.

Public Engagement and the Power of the Petition

One of the campaign’s most compelling tools was the public petition, which gathered over 90,000 signatures in its early years. This grassroots momentum added pressure on pharmaceutical companies and research institutions to commit publicly to transparency.

Major players like GSK and Johnson & Johnson acknowledged the movement, with GSK stating its commitment to post all results on its public register. Such corporate statements were seen as milestones in voluntary disclosure adoption by industry giants.

Integration with Broader Movements and Academic Research

AllTrials is closely aligned with the broader Open Science movement, which advocates for data sharing, reproducibility, and equitable access to research outputs. In academia, journals increasingly require trial registration as a precondition for publishing results, following guidelines by ICMJE and CONSORT.

Independent academic assessments have also validated the campaign’s impact. A 2020 study in PLOS Medicine showed significant improvements in results disclosure rates among large academic sponsors post-AllTrials. However, smaller institutions and investigator-initiated studies still lag behind.

Challenges: Enforcement, Monitoring, and Legacy Data

Despite the momentum, several challenges persist:

• Lack of enforcement for retrospective trials—especially pre-2007 data
• Inconsistent registry use outside of high-income countries
• Resource constraints at investigator-initiated research sites
• Limited punitive mechanisms for non-compliance

Furthermore, while some regulators have built trial data portals, interoperability and public usability vary significantly. For instance, the EU CTR and ClinicalTrials.gov differ in how they present and access summary results. Organizations like ClinicalStudies.in now play a role in bridging knowledge and training gaps for research teams globally.

Conclusion and Future Directions

The AllTrials campaign succeeded in raising global awareness about hidden data in clinical research and catalyzed regulatory and ethical reform. However, its work is far from complete. Strengthening enforcement, addressing non-reporting in low-resource settings, and ensuring accessibility of legacy data remain high-priority issues.

Transparency isn’t just a compliance box—it is a foundational pillar of good science and public trust. Sponsors, CROs, academic institutions, and regulatory bodies must continue to collaborate, ensuring that the vision of AllTrials—All Trials Registered. All Results Reported.—becomes a reality for all clinical research stakeholders.

For a deeper dive into global registry tools, visit EMA’s registry platform or access training resources on protocol transparency at PharmaValidation.in.

Expanding Rare Disease Trial Access Through Global Patient-Centric Strategies

Why Global Recruitment Is Essential for Rare Disease Trials

Most rare diseases affect a small number of individuals—typically fewer than 200,000 in the U.S., and often less than 1 in 2,000 in the EU. When ultra-rare diseases are involved, patient populations may fall below 100 worldwide. Relying on a single country or region for recruitment is insufficient and often leads to under-enrolled studies and regulatory delays.

Global recruitment enables sponsors to access a broader pool of eligible participants, enhance diversity, and accelerate development timelines. It also supports equitable inclusion, allowing patients in low-resource or underserved regions to benefit from investigational therapies. However, these benefits come with logistical, cultural, and regulatory complexities that must be addressed thoughtfully.

Key Challenges in Global Patient Accessibility

Despite the necessity, executing global rare disease trials is complex. Challenges include:

• Geographic Dispersion: Patients may live in remote or rural areas with limited trial infrastructure
• Language Barriers: Informed consent and study materials must be accurately translated
• Regulatory Fragmentation: Varying ethics approvals, import/export laws, and data protection requirements
• Economic Constraints: Travel costs and access limitations in low- and middle-income countries
• Healthcare Disparities: Variability in diagnostic availability and baseline care standards

Proactively addressing these barriers ensures compliance and improves participant retention and safety.

Multilingual and Culturally Adapted Study Materials

Language and cultural context can significantly influence a patient’s understanding and willingness to participate in a clinical trial. All essential study documents—including informed consent forms (ICFs), recruitment brochures, ePRO instructions, and adverse event guides—should be translated and culturally validated.

Best practices include:

• Using professional medical translators with rare disease experience
• Back-translation to ensure fidelity of meaning
• Incorporating cultural beliefs, health literacy, and local idioms in communication

For example, in a global trial for Gaucher Disease, sponsors translated ICFs into 12 languages and conducted community orientation sessions to ensure comprehension across South America, Asia, and Africa.

Cross-Border Site Selection and Infrastructure Assessment

To enable broad access, sponsors must carefully select trial sites based on not only geography but also infrastructure and feasibility. Key evaluation criteria include:

• Availability of disease specialists or diagnostic services
• Experience with rare or orphan disease trials
• Availability of IRB/EC for timely ethics reviews
• Capability for remote monitoring or decentralized models

Strategic inclusion of tertiary hospitals in developing countries—paired with decentralized services—can unlock access to underserved populations without compromising data quality.

Decentralized Technologies for International Access

Decentralized clinical trial (DCT) models are a key enabler of global accessibility. By allowing patients to participate from home or nearby clinics, DCT tools reduce the need for international travel and streamline multi-country studies.

Core elements of global DCT strategies:

• Telemedicine platforms with multilingual capabilities
• eConsent compliant with local regulations
• Wearables for real-time endpoint collection
• Mobile healthcare services (e.g., phlebotomy, nursing)

Reference case: In a Niemann-Pick trial, decentralized methods allowed patients from Argentina, Nigeria, and the Philippines to participate through local blood draws and tele-assessments.

Harmonizing Global Regulatory Submissions

One of the biggest bottlenecks in global trials is regulatory diversity. Sponsors must navigate varying requirements related to:

• Clinical trial application formats (e.g., EU CTA, US IND)
• Import/export licenses for investigational product (IP)
• Data privacy (GDPR in EU, HIPAA in US, country-specific laws)
• Informed consent regulations and patient compensation guidelines

Strategies to address these include:

• Early engagement with regulatory consultants in each country
• Utilization of joint review procedures like Voluntary Harmonization Procedure (VHP) in Europe
• Aligning trial master files and templates globally

Working with globally experienced CROs and leveraging guidance from sources like CTRI India can streamline approvals.

Supporting Travel and Logistics for International Participants

Where remote participation is not feasible, travel support becomes essential. This includes:

• Flight and visa support
• Hotel arrangements and ground transport
• Financial support for meals and lost income

Third-party logistics vendors such as World Courier or Greenphire specialize in these services for international trials. All costs should be disclosed during consent and approved by ethics committees.

Cross-Cultural Patient and Caregiver Engagement

Building trust and long-term relationships with patients and caregivers across cultures is critical for trial success. Sponsors must ensure ongoing communication through culturally sensitive channels, such as:

• Community health workers and local advocacy groups
• Translated newsletters, trial portals, and helplines
• Video diaries and mobile apps with caregiver support features

Example: In a pediatric trial for a rare epilepsy syndrome, video tutorials in 5 languages with voiceovers led to 25% higher caregiver compliance with at-home data collection protocols.

Data Monitoring, Oversight, and Quality Assurance

Global trials require robust data oversight mechanisms. Quality should never be compromised due to geographic scale. Recommendations include:

• Centralized data review hubs with multilingual monitors
• Remote SDV (source data verification) using secure portals
• Geo-tagged patient logs and timestamped eDiary entries
• Global SOP harmonization with site-specific customization

Regulatory authorities such as FDA and EMA expect full traceability of global data. Cloud-based eTMFs and audit readiness platforms help maintain compliance across borders.

Case Study: Global Rare Disease Trial in Alström Syndrome

Alström Syndrome, affecting fewer than 1,000 individuals globally, was the focus of a multi-site, global trial spanning the UK, Turkey, Brazil, and South Korea.

• Global registries identified 34 potential participants across 5 countries
• Multilingual tele-consent enabled patient enrollment in rural areas
• Mobile labs and wearable data collection reduced site visits by 60%

Result: The trial enrolled 22 patients in 4 months and met primary endpoints with high retention and positive patient-reported experience scores.

Conclusion: Global Strategies Are Key to Equity in Rare Disease Research

Rare disease patients live everywhere—and so must clinical research. By deploying global recruitment strategies that combine decentralized technologies, regulatory harmonization, and culturally sensitive engagement, sponsors can ensure that rare disease patients—regardless of geography—have a fair chance to participate in and benefit from clinical trials.

The future of rare disease drug development depends not just on science, but on breaking down geographic, linguistic, and economic barriers to access.